TABLE 2.
Inhibitory effects of the Skp2 inhibitors or inhibiting compounds in various kinds of tumors at cellular level.
| Tumor type | Cell line | Compound | Treatment time | IC50 |
|---|---|---|---|---|
| Prostate Carcinoma | ||||
| PC3 | SZL-P1-41 | 4 days | 5.61 μM(Chan et al., 2013) | |
| Parental PC3 | Gartanin | 72 h | 13.56 ± 0.20 μM(Pham et al., 2020) | |
| quiescent PC-3 | Safranal | 72 h | 0.109 ± 0.002 mM(Jiang et al., 2020) | |
| proliferative PC-3 | Safranal | 48 h | 0.512 ± 0.038 mM(Jiang et al., 2020) | |
| LNCaP | SZL-P1-41 | 4 days | 1.22 μM(Chan et al., 2013) | |
| LNCaP-S14 | SMIP004 | 72 h | 1.09 μM(Rico-Bautista et al., 2010) | |
| LNCaP-WT | SMIP004 | 72 h | 40 μM(Rico-Bautista et al., 2010) | |
| quiescent LNCaP | Safranal | 72 h | 0.133 ± 0.034 mM(Jiang et al., 2020) | |
| proliferative LNCaP | Safranal | 48 h | 0.234 ± 0.023 mM(Jiang et al., 2020) | |
| parental 22Rv1 | Gartanin | 72 h | 8.32 ± 0.18 μM(Pham et al., 2020) | |
| Lung Carcinoma | ||||
| H460 | SZL-P1-41 | 4 days | 5.15 μM(Chan et al., 2013) | |
| SKPin C1 | 72 h | 33 ± 12 μM(Zhao et al., 2020) | ||
| MLN4924 | 72 h | 0.43 ± 0.08 μM(Zhao et al., 2020) | ||
| Flavokawain A | 72 h | 19 ± 8.9 μM(Zhao et al., 2020) | ||
| A549 | SZL-P1-41 | 4 days | 5.36 μM(Chan et al., 2013) | |
| SMIP004 | 24 h | 500 nM(Huang et al., 2017) | ||
| H1299 | SZL-P1-41 | 4 days | 10.5 μM(Chan et al., 2013) | |
| H3255 | SZL-P1-41 | 4 days | 5.38 μM(Chan et al., 2013) | |
| H520 | SKPin C1 | 72 h | 7.3 ± 2.1 μM(Zhao et al., 2020) | |
| MLN4924 | 72 h | >10 μM(Zhao et al., 2020) | ||
| Flavokawain A | 72 h | 18 ± 11 μM(Zhao et al., 2020) | ||
| H69 | SKPin C1 | 72 h | 1.2 ± 0.6 μM(Zhao et al., 2020) | |
| MLN4924 | 72 h | 8.7 ± 1.1 μM(Zhao et al., 2020) | ||
| Flavokawain A | 72 h | 9.9 ± 2.3 μM(Zhao et al., 2020) | ||
| H146 | SKPin C1 | 72 h | 5.3 ± 0.8 μM(Zhao et al., 2020) | |
| MLN4924 | 72 h | 0.15 ± 0.02 μM(Zhao et al., 2020) | ||
| H196 | SKPin C1 | 72 h | 8.0 ± 2 μM(Zhao et al., 2020) | |
| MLN4924 | 72 h | 12 ± 8 μM(Zhao et al., 2020) | ||
| H720 | SKPin C1 | 72 h | 0.85 ± 0.15 μM(Zhao et al., 2020) | |
| MLN4924 | 72 h | 0.015 ± 0.005 μM(Zhao et al., 2020) | ||
| Primary mouse SCLC lung cell | SKPin C1 | 72 h | 0.70 ± 0.05 μM(Zhao et al., 2020) | |
| MLN4924 | 72 h | 1.8 ± 0.21 μM(Zhao et al., 2020) | ||
| Flavokawain A | 72 h | 8.3 ± 4.1 μM(Zhao et al., 2020) | ||
| Primary mouse SCLC liver metastatic cell | SKPin C1 | 72 h | 0.63 ± 0.16 μM(Zhao et al., 2020) | |
| MLN4924 | 72 h | 0.18 ± 0.08 μM (Zhao et al., 2020) | ||
| Flavokawain A | 72 h | 12 ± 2.7 μM(Zhao et al., 2020) | ||
| Hepatocellular Carcinoma | ||||
| HepG2 | Longikaurin A | 36 h | 5.13 μM(Liao et al., 2014) | |
| Hep3B | SZL-P1-41 | 4 days | 9.84 μM (Chan et al., 2013) | |
| SMMC-7721 | Longikaurin A | 36 h | 2.75 μM(Liao et al., 2014) | |
| BEL-7402 | Longikaurin A | 36 h | 6.83 μM(Liao et al., 2014) | |
| Huh7 | Longikaurin A | 36 h | 7.12 μM(Liao et al., 2014) | |
| Breast Carcinoma | ||||
| MCF-7/HER2 | Flavokawain A | 72 h | 13.6 μM(Jandial et al., 2017) | |
| MCF10A | Flavokawain A | 72 h | >100 μM (Jandial et al., 2017) | |
| SKBR3 | Flavokawain A | 72 h | 10 μM (Jandial et al., 2017) | |
| tsFT210 | Linichlorin A | 48 h | 1.6 μM(Ooi et al., 2013) | |
| Gentian violet | 48 h | 0.6 μM(Ooi et al., 2013) | ||
| Osteosarcoma | ||||
| U2OS | SZL-P1-41 | 4 days | 5.41 μM(Chan et al., 2013) | |
| SaOS-2 | Flavokawain A | 72 h | 7.5 μg/mL(Zhang et al., 2018) | |
| Saos-LM7 | Flavokawain A | 72 h | 7.5 μg/mL(Zhang et al., 2018) | |
| 143B | Flavokawain A | 72 h | 7.5 μg/mL (Zhang et al., 2018) | |
| Cervical cancer | ||||
| HeLa | Linichlorin A | 48 h | 3.2 μM(Ooi et al., 2013) | |
| Gentian violet | 48 h | 0.4 μM(Ooi et al., 2013) | ||
| Leukemia T cell leukemia | ||||
| TAIL7 | SZL-P1-41 | 96 h | 30 μM(Rodriguez et al., 2020) | |
| SKPin C1 | 96 h | 2.4 μM(Rodriguez et al., 2020) | ||
| Molt4 | SKPin C1 | 96 h | 2.6 μM(Rodriguez et al., 2020) | |
| HPB-ALL | SKPin C1 | 96 h | 2.0 μM(Rodriguez et al., 2020) | |
| SupT1 | SKPin C1 | 96 h | 1.9 μM(Rodriguez et al., 2020) | |
| JurKat | SKPin C1 | 96 h | 1.6 μM(Rodriguez et al., 2020) | |
| CEM | SKPin C1 | 96 h | 1.1 μM(Rodriguez et al., 2020) | |
| Loucy | SKPin C1 | 96 h | 1.1 μM(Rodriguez et al., 2020) | |
| Human primary T-ALL | SKPin C1 | 48 h | 1.72 μM(Rodriguez et al., 2020) | |
| Myeloid Leukemia | ||||
| HL-60 | Linichlorin A | 72 h | 1.2 ± 0.6 μM(Estevez-Sarmiento et al., 2020) | |
| U-937 | Linichlorin A | 72 h | 1.9 ± 0.5 μM(Estevez-Sarmiento et al., 2020) | |
| U-937/Bcl-2 | Linichlorin A | 72 h | 2.9 ± 1.8 μM(Estevez-Sarmiento et al., 2020) | |
| K562 | Diosmetin | 48 h | 8.42 μM(Liu et al., 2020a) | |
| KBM5 | Diosmetin | 48 h | 8.52 μM(Liu et al., 2020a) | |
| KBM5-T3151 | Diosmetin | 48 h | 6.46 μM(Liu et al., 2020a) | |
| Urinary bladder Carcinoma | ||||
| TCCSUP | Flavokawain A | 48 h | 10.55 μM (Tang et al., 2008) | |
| HT1197 | Flavokawain A | 48 h | 7.9 μM (Tang et al., 2008) | |
| 5637 | Flavokawain A | 48 h | 13.1 μM (Tang et al., 2008) | |
| T24 | Flavokawain A | 48 h | 16.7 μM (Tang et al., 2008) | |
| UMUC3 | Flavokawain A | 48 h | 17.7 μM (Tang et al., 2008) | |
| HT1376 | Flavokawain A | 48 h | 14.7 μM (Tang et al., 2008) | |
| J82 | ABT-751 | 24 h | >3 μM(Dehghanian et al., 2021) | |
| ABT-751 | 48 h | 0.7 μM(Dehghanian et al., 2021) | ||
| ABT-751 | 72 h | 0.37 μM (Dehghanian et al., 2021) | ||
| BFTC905 | ABT-751 | 24 h | >3 μM (Dehghanian et al., 2021) | |
| ABT-751 | 48 h | 0.6 μM (Dehghanian et al., 2021) | ||
| ABT-751 | 72 h | 0.4 μM (Dehghanian et al., 2021) | ||
| Glioblastoma | ||||
| U251 | Curcumin | 72 h | 15 μM (Wang et al., 2015) | |
| SNB19 | Curcumin | 72 h | 15 μM (Wang et al., 2015) | |
| Melanoma | ||||
| SK-MEL-1 | Linichlorin A | 72 h | 3.6 ± 1.3 μM | |
| MUM2B | SKPin C1 | 4 days | 0.86 μM (Zhao et al., 2019) | |
| OM431 | SKPin C1 | 4 days | 1.83 μM (Zhao et al., 2019) | |
| Endometrial Carcinoma | ||||
| ECC-1 | Skp2E3Li C2 | 48 h | EC50 = 14.3 μM (Pavlides et al., 2013) | |
| Colorectal Carcinoma | ||||
| HCT116 | 7-azaindoles (Compound 5) | 72 h | EC50 = 4.7 μM (Altmann et al., 2017) | |
| 7-azaindoles (Compound 6) | 72 h | EC50 = 4.9 μM (Altmann et al., 2017) | ||
| Pancreatic Carcinoma | ||||
| Patu8988 | Curcumin | 72 h | 10 μM (Su et al., 2016b) | |
| Panc-1 | Curcumin | 72 h | 15 μM (Su et al., 2016b) | |
aLNCaP-S14: positive LNCaP clone with stable Skp2 overexpression U-937/Bcl-2: U-937 cell overexpressing Bcl-2.